CoLucid Pharmaceuticals
Developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
Launch date
Employees
Market cap
-
Enterprise valuation
€873m (Public information from Jan 2017)
Cambridge Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$16.5m | Series A | ||
$25.0m | Series B | ||
N/A | $9.2m | Early VC | |
N/A | $2.0m | Debt | |
$7.5m | Early VC | ||
$37.1m | Series C | ||
N/A | N/A | IPO | |
* | $960m Valuation: $960m | Acquisition | |
Total Funding | €86.6m |
Related Content
Recent News about CoLucid Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.